Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease

O. Rascol; N. Fabre; O. Blin; J. Poulik; U. Sabatini; J. M. Senard; M. Ane; J. L. Montastruc; A. Rascol

doi:10.1002/mds.870090410

Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease

O. Rascol, N. Fabre, O. Blin, J. Poulik, U. Sabatini, J. M. Senard, M. Ane, J. L. Montastruc, A. Rascol

Fondazione Santa Lucia

Research output: Contribution to journal › Article › peer-review

Abstract

One month of adjunct treatment with naltrexone (100 mg/day) was compared with placebo in a double-blind, randomized, cross-over design in two groups of patients with Parkinson's disease. The first group was composed of 10 patients with a moderate motor impairment insufficiently controlled by monotherapy with bromocriptine. The second group was composed of eight patients with L-dopa-induced peak-dose dyskinesia. Naltrexone as compared with placebo did not demonstrate any significant change in motor function in either group. These negative clinical results do not support a significant role of endogenous opioid systems in the pathophysiology of motor impairment in Parkinson's disease.

Original language	English
Pages (from-to)	437-440
Number of pages	4
Journal	Movement Disorders
Volume	9
Issue number	4
DOIs	https://doi.org/10.1002/mds.870090410
Publication status	Published - 1994

Keywords

Motor symptoms
Naltrexone
Parkinson's disease

ASJC Scopus subject areas

Clinical Neurology
Neuroscience(all)

Access to Document

10.1002/mds.870090410

Cite this

@article{9e4dd5b85b62476f8b13f0a4631a6e95,

title = "Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease",

abstract = "One month of adjunct treatment with naltrexone (100 mg/day) was compared with placebo in a double-blind, randomized, cross-over design in two groups of patients with Parkinson's disease. The first group was composed of 10 patients with a moderate motor impairment insufficiently controlled by monotherapy with bromocriptine. The second group was composed of eight patients with L-dopa-induced peak-dose dyskinesia. Naltrexone as compared with placebo did not demonstrate any significant change in motor function in either group. These negative clinical results do not support a significant role of endogenous opioid systems in the pathophysiology of motor impairment in Parkinson's disease.",

keywords = "Motor symptoms, Naltrexone, Parkinson's disease",

author = "O. Rascol and N. Fabre and O. Blin and J. Poulik and U. Sabatini and Senard, {J. M.} and M. Ane and Montastruc, {J. L.} and A. Rascol",

year = "1994",

doi = "10.1002/mds.870090410",

language = "English",

volume = "9",

pages = "437--440",

journal = "Movement Disorders",

issn = "0885-3185",

publisher = "John Wiley and Sons Inc.",

number = "4",

}

TY - JOUR

T1 - Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease

AU - Rascol, O.

AU - Fabre, N.

AU - Blin, O.

AU - Poulik, J.

AU - Sabatini, U.

AU - Senard, J. M.

AU - Ane, M.

AU - Montastruc, J. L.

AU - Rascol, A.

PY - 1994

Y1 - 1994

N2 - One month of adjunct treatment with naltrexone (100 mg/day) was compared with placebo in a double-blind, randomized, cross-over design in two groups of patients with Parkinson's disease. The first group was composed of 10 patients with a moderate motor impairment insufficiently controlled by monotherapy with bromocriptine. The second group was composed of eight patients with L-dopa-induced peak-dose dyskinesia. Naltrexone as compared with placebo did not demonstrate any significant change in motor function in either group. These negative clinical results do not support a significant role of endogenous opioid systems in the pathophysiology of motor impairment in Parkinson's disease.

AB - One month of adjunct treatment with naltrexone (100 mg/day) was compared with placebo in a double-blind, randomized, cross-over design in two groups of patients with Parkinson's disease. The first group was composed of 10 patients with a moderate motor impairment insufficiently controlled by monotherapy with bromocriptine. The second group was composed of eight patients with L-dopa-induced peak-dose dyskinesia. Naltrexone as compared with placebo did not demonstrate any significant change in motor function in either group. These negative clinical results do not support a significant role of endogenous opioid systems in the pathophysiology of motor impairment in Parkinson's disease.

KW - Motor symptoms

KW - Naltrexone

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=0027958852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027958852&partnerID=8YFLogxK

U2 - 10.1002/mds.870090410

DO - 10.1002/mds.870090410

M3 - Article

C2 - 7969211

AN - SCOPUS:0027958852

VL - 9

SP - 437

EP - 440

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 4

ER -

Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this